Reference Materials for Measurable Residual Disease (MRD) Monitoring

 

Determining and using the most effective and safest treatment is of great importance in cancer disease management. Recently, a potential biomarker has been identified in immunotherapy: tumor mutational burden (TMB), an assessment of the number of relevant mutations in a tumor.

Reference Materials for Measurable Residual Disease (MRD) Monitoring

The analytical validation of liquid biopsy-based assays that attempt to monitor for the disappearance and reemergence of cancer can be challenging due to the need for reference materials that allow for the assessment of sensitivity and specificity at variant allele frequencies (VAFs) that can be over an order of magnitude below those that can be detected reliably by typical circulating tumor DNA (ctDNA) assays. Download this free poster to learn about how we characterized our reference materials for MRD Monitoring.

Fill out the form to download our free poster.

Complete this form for your free download:

We’re committed to your privacy. SeraCare will not share or sell your data. View our privacy policy below for details.